Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Breast Cancer: the REPEAT Trial

NCT06640881 · tracked via the Priya Life Science Netherlands tracker

Sponsor

Amsterdam UMC, location VUmc

Phase

Phase 2

Started

2025-01-01

Last updated

2026-07-16

Condition(s) studied

Recurrent Breast CarcinomaIpsilateral Recurrence

Investigational drug(s) / intervention(s)

ablative single-dose PBI

ablative single-dose PBI: ablative single-dose PBI followed by BCS after three weeks At baseline (prior to RT) and prior to BCS, toxicity, PROMS and cosmetic outcome will be assessed. Additionally, a preoperative MRI will be performed three weeks following RT to evaluate the acute tumor response.

Study summary

Over the past decades, interest in second breast-conserving therapy (BCT) has increased due to, among others, advancements in radiotherapy techniques. Preoperative partial breast irradiation (PBI) is an experimental treatment for patients with low-risk primary breast cancer. This approach can downstage the tumor, and may possibly reduce toxicity and improve cosmetic outcomes compared to postoperative radiotherapy. This study aims to evaluate the feasibility of single-dose preoperative PBI and second breast-conserving surgery (BCS) for patients with an ipsilateral recurrent breast event (IRBE) after previous BCT.

The REPEAT trial is a multicenter, prospective, single-arm trial investigating ablative single-dose preoperative PBI in patients with an IRBE. Eligible patients are ≥ 50 years, have a unifocal non-lobular invasive breast cancer ≤ 2 cm, Bloom-Richardson grade 1 or 2, estrogen receptor-positive, HER2-negative and clinically negative axillary lymph nodes. The study plans to enroll 25 patients. Radiotherapy planning will involve the use of CT and MRI in the treatment position. Single-dose PBI of 20 Gy to the tumor and 15 Gy to the surrounding 2 cm of breast tissue will be delivered using a conventional or MR-guided linear accelerator. Tumor response will be monitored preoperatively using MRI and liquid biopsies to identify biomarkers for evaluating radiosensitivity. BCS will be performed 3 weeks post-PBI. The primary endpoint is the incidence of grade 2 or higher treatment-associated acute toxicity within 90 days. Secondary endpoints include the evaluation of acute (grade 1) and late toxicity, radiologic and pathologic response, mastectomy rate, patient-reported outcomes, cosmetic outcome, local, regional and distant recurrence rates, survival outcome, and biomarkers in liquid biopsies and tumor tissue. Patients will be followed up to 5 years after PBI.

This trial will evaluate the feasibility of single-dose preoperative PBI and BCS for patients with IRBE. This treatment approach is expected to minimize the irradiated volume, reduce toxicity, and improve cosmetic outcomes compared to postoperative PBI after second BCS. Identifying biomarkers for radiosensitivity will help in selection patients and tailoring treatment.

Eligibility

Sex

FEMALE

Min age

50 Years

Max age

—

Healthy volunteers

Inclusion criteria: * WHO performance scale ≤ 2 * Females at least 50 years of age with an ipsilateral invasive breast cancer event or DCIS (i.e. recurrence, second primary) after previous breast conserving surgery and radiotherapy (for invasive breast cancer/carcinoma in situ) * Tumor characteristics: - - Tumor size ≤ 2 cm, unifocal on MRI On tumor biopsy: * Bloom-Richardson grade 1 or 2, * non-lobular invasive histological type carcinoma, * accompanying (non-extensive) DCIS is accepted within the tumor size of 2 cm on mammography and/or tumor biopsy, including no non-mass enhancement on MRI, * ER-positive and HER2-negative tumor, * No lymphovascular invasion. * Clinical node negative on PET-CT, ultrasound and MRI * No distant metastases * Repeat breast-conserving surgery is feasible, if no or mild late toxicity (no grade 2 or higher) from previous breast-conserving therapy * Adequate communication and understanding skills of the Dutch language * Written informed consent Exclusion criteria: * Ipsilateral invasive breast cancer recurrence less than 2 years after first breast conserving therapy for breast cancer or ductal carcinoma in situ * Legal incapacity * Known breast cancer mutation gene carrier * Previous ipsilateral mastectomy * Collagen synthesis disease (e.g. Osteogeneis imperfecta, Ehlers-Danlos syndrome, systemic lupus erythematosus) * Invasive lobular carcinoma * MRI absolute contraindications as defined by the Department of Radiology * Indication for treatment with neoadjuvant chemotherapy * Non-feasible dosimetric RT plan * Breast implants

Primary outcome measure(s)

Acute toxicity — 90 days
The incidence of grade 2 or higher treatment-associated acute toxicity within 90 days

Trial sites (1)

Facility	City	Region	Status
Amsterdam UMC / VU Medical Centre	Amsterdam	Netherlands	Recruiting

More Amsterdam UMC, location VUmc trials in the Netherlands

Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques Recruiting

ORthosis vs No Orthosis After Surgically Treated Traumatic Thoracolumbar Fractures Recruiting

Prevention of Opioid-induced Constipation in Patients With Advanced Cancer Recruiting

Dutch-Depression Outcome Trial Comparing 5 Day Multi Daily Neuronavigated Theta Burst Sessions With 6 Weeks rTMS Recruiting

Validating Digital Biomarkers to Detect Disease Activity and Disease Progression in Multiple Sclerosis Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06640881 on ClinicalTrials.gov ↗ ← All trials in the Netherlands